@dickdocsg's testosterone cypionate guide fact-checked

What did @dickdocsg actually say?

The creator, presenting as a doctor, gave a quick rundown of testosterone cypionate administration. He described it as "a short acting testosterone" given by injection, said the standard method is intramuscular every one to two weeks, and mentioned a newer subcutaneous approach using "a smaller dose by every other day." He closed by telling viewers to consult a doctor to see if they're suitable.

That's a fairly compact explainer. But the "short acting" description is the kind of thing that makes endocrinologists wince, and it's worth unpacking whether the rest of the advice holds up under scrutiny.

Does the science back this up?

Mostly, but not on the short-acting claim. The pharmacokinetics of testosterone cypionate are well-established, and this is not a short-acting compound by any reasonable clinical definition. The subcutaneous dosing approach, however, is legitimate and increasingly supported by evidence.

Testosterone cypionate has a half-life of approximately 8 days, which places it firmly in the long-acting ester category. After a single intramuscular injection, serum testosterone peaks within 24-72 hours and remains elevated for 7-14 days (Dobs et al., 1999, Journal of Clinical Endocrinology and Metabolism). That is the opposite of short-acting. Short-acting testosterone preparations include aqueous testosterone suspension, which clears within hours.

On subcutaneous dosing: a 2012 study by Olsson et al. in the International Journal of Andrology confirmed that subcutaneous testosterone cypionate produces stable serum levels with smaller, more frequent doses. A later analysis by Spratt et al. (2017, Journal of the Endocrine Society) found subcutaneous delivery produced less peak-to-trough variability than traditional intramuscular protocols, which is a real clinical advantage for some patients.

What did they get wrong (or right)?

The short-acting label is wrong, and it matters. The right thing: the subcutaneous dosing information is accurate and reflects current clinical practice.

Calling testosterone cypionate "short acting" is not a minor slip. It could genuinely confuse a patient managing their own TRT. If someone thinks they're on a short-acting testosterone, they might expect faster clearance, faster symptom relief, or a different safety profile than what cypionate actually delivers. The distinction between ester types, short (suspension, propionate), medium (cypionate, enanthate), and long (undecanoate), matters for injection scheduling, side effect timing, and how quickly the compound clears the body if something goes wrong.

What the creator did get right: intramuscular injection every one to two weeks is the standard licensed dosing interval for testosterone cypionate. And the mention of subcutaneous every-other-day dosing is clinically relevant. This method is used in practice to smooth out hormonal fluctuations, particularly for patients sensitive to the peaks and troughs of less frequent injections. The advice to consult a doctor is appropriate, even if brief.

What should you actually know?

Testosterone cypionate is a long-acting ester, not short-acting. That distinction changes how the drug behaves in your body and how clinicians monitor it.

The half-life of roughly 8 days means levels build up over several injection cycles before reaching steady state, typically after 3-4 injections. This is why symptoms may not fully resolve for weeks after starting TRT. It also means that if you experience side effects, such as elevated hematocrit or estrogen-related symptoms, the drug does not simply clear quickly.

On administration routes: intramuscular injection into the gluteal muscle or vastus lateralis remains the most widely used method. Subcutaneous injection into abdominal or thigh fat is gaining traction in TRT clinics because it reduces injection site discomfort and produces more stable serum levels at doses typically ranging from daily to every-other-day. Neither route is universally superior; the best approach depends on individual factors including body composition, tolerance, and treatment goals.

• Testosterone cypionate is a long-acting ester with an approximate 8-day half-life, not short-acting.
• Intramuscular dosing every 1-2 weeks is standard, but produces larger hormonal swings than more frequent dosing.
• Subcutaneous every-other-day protocols are evidence-backed and used in regulated TRT settings.
• Any TRT protocol requires baseline bloodwork and ongoing monitoring of testosterone, hematocrit, PSA, and estradiol.